Jessica E Maxwell1, Scott K Sherman1, Thomas M O'Dorisio2, Andrew M Bellizzi3, James R Howe4. 1. Department of General Surgery, University of Iowa Carver College of Medicine, Iowa City, IA. 2. Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA. 3. Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA. 4. Department of General Surgery, University of Iowa Carver College of Medicine, Iowa City, IA. Electronic address: james-howe@uiowa.edu.
Abstract
INTRODUCTION: Neuroendocrine tumors (NETs) frequently metastasize to the liver. Operative debulking offers symptomatic relief and improved survival; however, the frequent presence of multifocal, bilobar disease and high recurrence rates introduces doubt regarding their optimal management. Parenchyma-sparing debulking (PSD) procedures (ablation, enucleation, wedge resections) may offer similar survival improvements as resection while minimizing morbidity and preserving functional liver tissue. METHODS: Clinicopathologic variables from 228 patients with small bowel or pancreatic NETs managed operatively at one institution were collected. Liver-directed surgery was carried out when substantial debulking was deemed feasible. Survival was assessed by use of the Kaplan-Meier method. RESULTS: A total of 108 patients with pancreatic NET or small bowel NET underwent liver-directed surgery with primarily PSD procedures. Nearly two-thirds of patients achieved 70% cytoreduction and 84% had concurrent resection of their primary. The median number of lesions treated was 6 (range, 1-36). There were no 30-day operative mortalities. The 30-day major complication rate was 13.0%. Patients who achieved 70% cytoreduction enjoyed improved progression free (median 3.2 years) and overall survival (median not reached). CONCLUSION: PSD procedures are safe and can achieve significant cytoreduction, which is associated with improved survival. Lowering the debulking target threshold to 70% may benefit NET patients by increasing eligibility for cytoreduction.
INTRODUCTION:Neuroendocrine tumors (NETs) frequently metastasize to the liver. Operative debulking offers symptomatic relief and improved survival; however, the frequent presence of multifocal, bilobar disease and high recurrence rates introduces doubt regarding their optimal management. Parenchyma-sparing debulking (PSD) procedures (ablation, enucleation, wedge resections) may offer similar survival improvements as resection while minimizing morbidity and preserving functional liver tissue. METHODS: Clinicopathologic variables from 228 patients with small bowel or pancreatic NETs managed operatively at one institution were collected. Liver-directed surgery was carried out when substantial debulking was deemed feasible. Survival was assessed by use of the Kaplan-Meier method. RESULTS: A total of 108 patients with pancreaticNET or small bowelNET underwent liver-directed surgery with primarily PSD procedures. Nearly two-thirds of patients achieved 70% cytoreduction and 84% had concurrent resection of their primary. The median number of lesions treated was 6 (range, 1-36). There were no 30-day operative mortalities. The 30-day major complication rate was 13.0%. Patients who achieved 70% cytoreduction enjoyed improved progression free (median 3.2 years) and overall survival (median not reached). CONCLUSION: PSD procedures are safe and can achieve significant cytoreduction, which is associated with improved survival. Lowering the debulking target threshold to 70% may benefit NETpatients by increasing eligibility for cytoreduction.
Authors: Olov Norlén; Peter Stålberg; Kjell Öberg; John Eriksson; Jakob Hedberg; Ola Hessman; Eva Tiensuu Janson; Per Hellman; Göran Åkerström Journal: World J Surg Date: 2012-06 Impact factor: 3.352
Authors: Skye C Mayo; Mechteld C de Jong; Carlo Pulitano; Brian M Clary; Srinevas K Reddy; T Clark Gamblin; Scott A Celinksi; David A Kooby; Charles A Staley; Jayme B Stokes; Carrie K Chu; Alessandro Ferrero; Richard D Schulick; Michael A Choti; Giles Mentha; Jennifer Strub; Todd W Bauer; Reid B Adams; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2010-06-29 Impact factor: 5.344
Authors: Evan S Glazer; Jennifer F Tseng; Waddah Al-Refaie; Carmen C Solorzano; Ping Liu; Katherine A Willborn; Eddie K Abdalla; Jean-Nicolas Vauthey; Steven A Curley Journal: HPB (Oxford) Date: 2010-08 Impact factor: 3.647
Authors: J Philip Boudreaux; Yi-Zarn Wang; Anne E Diebold; Daniel J Frey; Lowell Anthony; Ann Porter Uhlhorn; Pamela Ryan; Eugene A Woltering Journal: J Am Coll Surg Date: 2014-01-10 Impact factor: 6.113
Authors: Timucin Taner; Thomas D Atwell; Lizhi Zhang; Trynda N Oberg; William S Harmsen; Seth W Slettedahl; Michael L Kendrick; David M Nagorney; Florencia G Que Journal: HPB (Oxford) Date: 2012-07-26 Impact factor: 3.647
Authors: D Elias; D Goéré; G Leroux; C Dromain; S Leboulleux; Th de Baere; M Ducreux; E Baudin Journal: Eur J Surg Oncol Date: 2009-05-21 Impact factor: 4.424
Authors: James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier Journal: Pancreas Date: 2020-01 Impact factor: 3.327
Authors: Thomas A Hope; Emily K Bergsland; Murat Fani Bozkurt; Michael Graham; Anthony P Heaney; Ken Herrmann; James R Howe; Matthew H Kulke; Pamela L Kunz; Josh Mailman; Lawrence May; David C Metz; Corina Millo; Sue O'Dorisio; Diane L Reidy-Lagunes; Michael C Soulen; Jonathan R Strosberg Journal: J Nucl Med Date: 2017-10-12 Impact factor: 10.057
Authors: Kendall J Keck; Jessica E Maxwell; Yusuf Menda; Andrew Bellizzi; Joseph Dillon; Thomas M O'Dorisio; James R Howe Journal: Surgery Date: 2016-11-15 Impact factor: 3.982
Authors: Kendall J Keck; Allen Choi; Jessica E Maxwell; Guiying Li; Thomas M O'Dorisio; Patrick Breheny; Andrew M Bellizzi; James R Howe Journal: Ann Surg Oncol Date: 2017-05-30 Impact factor: 5.344